SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

SurModics, Inc.

Minnesota		0-23837		41-1356149
(State of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

9924 West 74th Street
Eden Prairie, Minnesota		55344
(Address of Principal Executive Offices)		(Zip Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 5.02(b) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     On November 20, 2008, SurModics, Inc. (the “Company”) announced that Kendrick B. Melrose, Chairman of the Board of Directors, who had been a director of the Company since 1988 and who had served as Chairman since 2006, was retiring from the Board, effective immediately. Robert C. Buhrmaster, who has served as a director of the Company since January 2008, was elected by the Board to replace Mr. Melrose as Chairman.

     A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

     (d) Exhibits.

99.1

Press Release Dated February 2, 2009.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXHIBIT INDEX

Exhibit
Number		Description
Exhibit 99.1		Press Release issued by SurModics, Inc. dated February 2, 2009.

FOR IMMEDIATE RELEASE

SurModics Elects Robert C. Buhrmaster Chairman of the

Board; Kendrick B. Melrose to Retire

EDEN PRAIRIE, Minnesota – February 2, 2009 – SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced that its board of directors has elected Robert C. Buhrmaster chairman of the board, effective at today’s Annual Meeting of Shareholders. Buhrmaster succeeds Kendrick B. Melrose, 68, who is retiring from the Company’s board of directors. Melrose has been chairman of the board since August 2006, and has been a director since 1988.

Buhrmaster, 61, has been a director of SurModics since January 2008. He previously served as the President and Chief Executive Officer of Jostens, Inc., from 1994 to 2004 and as Chairman from 1998 to 2004. Prior to joining Jostens, Mr. Buhrmaster spent 18 years at Corning, Inc., serving in various roles, including senior vice president and general manager of several businesses, corporate controller and director of strategic planning.

“Serving as a board member has been a very rewarding experience for me. I will greatly miss the interactions with such a highly accomplished group of professionals and community leaders,” said Melrose. “I am honored to pass the chairmanship to Bob Buhrmaster, who brings tremendous depth of experience and keen business insights to his new role. His strategic sense and practical judgment have been important assets for the board and the management team. I have great confidence in Bob, the entire board, and the management team’s ability to continue leading SurModics toward its vast potential in developing and commercializing life-enhancing technologies and products.”

“I am delighted to have the opportunity to lead the SurModics board,” said Buhrmaster. “It will be a privilege to succeed Ken Melrose, an outstanding chairman, in this role. I look forward to working even more closely with Bruce Barclay and his talented management team.”

SurModics Elects Robert C. Buhrmaster Chairman of the Board; Kendrick B. Melrose to Retire
Page 2

“I want to thank Ken for his 20 years of tireless efforts on behalf of SurModics,” said Bruce Barclay, president and CEO. “His contributions to the success of this company are immeasurable, and he has been critical in helping drive our tremendous diversification and growth. We are extremely fortunate to have Bob Buhrmaster, an experienced advisor and skillful business leader, to succeed him. I look forward to teaming with Bob as SurModics continues to pursue its vision of extending and improving the lives of patients through technology innovation.”

About SurModics, Inc. SurModics’ vision is to extend and improve the lives of patients through technology innovation. The Company partners with the world’s foremost medical device, pharmaceutical and life science companies to develop and commercialize innovative products that result in improved diagnosis and treatment for patients. Core offerings include: drug delivery technologies (coatings, microparticles, nanoparticles, and implants); surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. SurModics is headquartered in Eden Prairie, Minnesota and its Brookwood Pharmaceuticals subsidiary is located in Birmingham, Alabama. For more information about the Company, visit www.surmodics.com. The content of SurModics’ website is not part of this release or part of any filings the Company makes with the SEC.

# # #

Contact

SurModics, Inc.
Phil Ankeny, Senior Vice President and Chief Financial Officer
(952) 829-2700